EUVIMEDAvasta EUVIMED
Open access

CES3 promotes NSCLC progression via lipid metabolic reprogramming regulated by TFAP2A

Pengfei Luo, Zirui Huang, Sijuan Ding, Zhangwen Tang, Yanhong Wei, Shaohui Jiang, Ruoting Tang, Fang Li, Han Yang, Lujun Zhao

Journal of Cancer · 2026-01-01 · 17 (1) · 99-108

DOI: 10.7150/jca.118395 ↗

At a glance

Journal article in Journal of Cancer, published on 2026-01-01. Written by Pengfei Luo and 9 co-authors. Institution: Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National C…. Cited 2 times so far (Crossref). The full text is freely available in PubMed Central.

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Metabolic reprogramming is an important feature in non-small cell lung cancer (NSCLC) that can result in therapeutic resistance. Exploring dysregulated lipid metabolism in NSCLC will accelerate the development of potential lipid biomarkers to target and control the malignant progression of NSCLC. In this study, RNA next-generation sequencing of 25 paired NSCLC specimens and adjacent normal tissues was used to find that carboxylesterase 3 (CES3) was upregulated in NSCLC. Knockdown of CES3 significantly inhibited NSCLC cell proliferation and invasion. Additionally, CES3 inhibition promoted lipid accumulation in NSCLC cells. Furthermore, we found transcription factor AP-2α (TFAP2A) could regulate CES3 levels in NSCLC. TFAP2A was found upregulated in NSCLC and correlated with poorer outcome. Inhibiting TFAP2A resulted in suppressed cell proliferation as well as invasion while increasing the lipid accumulation in NSCLC. CES3 overexpression could reverse the impact of TFAP2A inhibition on NSCLC progression. In summary, TFAP2A dysregulation resulted in CES3 overexpression and the following NSCLC tumorigenesis. Targeting the TFAP2A/CES3 axis may represent a promising therapeutic strategy for NSCLC in the future.

Subjects

Author keywords

carboxylesterase 3lipid metabolismnon-small cell lung cancerproliferationtranscription factor AP-2α

Authors and institutions

  • Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center…
  • Department of Oncology, The Central Hospital of Yongzhou, No. 396 Yiyun Road, Yongzhou City, 425000 Hunan Province, China. Hunan Provincial Demonstration Base for Medical Technology in Tumor Radiotherapy.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.

Cite

APA

Luo, P., Huang, Z., Ding, S., Tang, Z., Wei, Y., Jiang, S., Tang, R., Li, F., Yang, H., & Zhao, L. (2026). CES3 promotes NSCLC progression via lipid metabolic reprogramming regulated by TFAP2A. Journal of Cancer, 17(1), 99-108. https://doi.org/10.7150/jca.118395

Vancouver

Luo P, Huang Z, Ding S, Tang Z, Wei Y, Jiang S, et al. CES3 promotes NSCLC progression via lipid metabolic reprogramming regulated by TFAP2A. Journal of Cancer. 2026;17(1):99-108. doi:10.7150/jca.118395

BibTeX
@article{Luo2026,
  author = {Luo, Pengfei and Huang, Zirui and Ding, Sijuan and Tang, Zhangwen and Wei, Yanhong and Jiang, Shaohui and Tang, Ruoting and Li, Fang and Yang, Han and Zhao, Lujun},
  title = {CES3 promotes NSCLC progression via lipid metabolic reprogramming regulated by TFAP2A},
  journal = {Journal of Cancer},
  year = {2026},
  volume = {17},
  number = {1},
  pages = {99--108},
  doi = {10.7150/jca.118395}
}
Start for free →